Introduction
Coronary artery bypass graft surgery (CABG) is one of the most commonly performed major surgeries in the United States with over 397,000 CABG's performed in 2010. (Go, Mozaffarian et al. 2012 ) One of the most dreadful adverse sequelae of CABG is stroke which is also the 2 nd most common major post-operative complication seen with CABG, occurring in 1 to 5% of patients. (Furlan, Sila et al. 1992; Brown, Kugelmass et al. 2008 ) Patients suffering from postoperative stroke have a very high incidence of in-hospital mortality. (Hogue, Murphy et al. 1999 ) Studies have shown that presence of extracranial carotid artery stenosis (ECAS) is a strong risk factor for post-operative morbidity and mortality due post-CABG strokes. (Brown, Kugelmass et al. 2008) In this book chapter, we will review the epidemiology of concomitant coronary and carotid artery disease, the association with post-operative stroke, recommendations for pre-operative ECAS screening and management options for patients in whom ECAS is identified.
Co-prevalence of carotid and coronary artery disease and its implications on perioperative and postoperative morbidity and mortality: Atherosclerosis is a systemic disease which is usually present in multiple vascular beds simultaneously. (Beique, Ali et al. 2006 ) In a recent study from the Cleveland Clinic involving 45,432 patient's, presence of carotid artery disease was confirmed as a significant risk factor for perioperative stroke after CABG. (Tarakji, Sabik et al. 2011) In the REACH Registry which was comprised of 67,888 patients, 10% of patients had concomitant coronary artery disease (CAD) and cerebrovascular disease (CVD). Anastasiasdis et al evaluated carotid arteries in 307 patients undergoing CABG and reported that while 3 out of 4 patients undergoing CABG had carotid atherosclerosis, the majority of these (63%) had < 50% ECAS. (Anastasiadis, Karamitsos et al. 2009 ). Various studies have reported the incidence of ECAS with varies degree of stenosis among the patient populations undergoing CABG which are summarized in table 1. Interestingly, the likelihood of having ECAS increases with the underlying severity of CAD ( Table 2 ).
Severity of CAD Prevalence of Significant Carotid Atherosclerosis (%)
1-vessel CAD 5.3% 2-vessel CAD 13.5%
3-vessel CAD 24.5%
Left main disease 40% 
3-vessel CAD or left main disease 24%

Utility of advanced imaging carotid artery beyond carotid duplex ultrasound
Duplex ultrasound is an excellent tool to diagnose ECAS. (Eagle, Guyton et al. 1999 ) However there are certain inherent errors that can occur with duplex. The presence of calcification at the site of stenosis may cause underestimation of degree of stenosis; similarly contralateral occlusion may lead to falsely elevated velocities in the ipsilateral carotid artery leading to overestimation of the degree of stenosis. (Mitchell E 2004) In such situations additional imaging with computed tomography angiography (CTA) or magnetic resonance angiography (MRA) may further characterize the degree of stenosis as well as provide insight on plaque charac-teristics, aortic pathology and intracranial ICA abnormalities. Given the excellent images rendered by CTA or MRA, conventional angiography is rarely required for determining degree of stenosis among those with normal or minimally impaired renal function. For those with moderate to severe chronic kidney disease, MRI may be relatively contraindicated due to the risk of nephrogenic systemic sclerosis and invasive angiography favored over CTA given its lower relative contrast volume and risk of contrast-induced acute kidney injury.
Other factors that may lead to increased stroke risk beyond degree of stenosis, including cerebrovascular reserve (CVR). Severe ECAS reduces cerebral perfusion pressure. Autoregulation of the cerebral vasculature dilates the cerebral arterioles maximally, and with further reduction in cerebral perfusion, blood flow will eventually decrease, causing impairment in cerebral perfusion leading to stroke. CVR can be assessed by two approaches. the first, CVR can be determined through direct measurements of brain tissue with flow-sensitive imaging through positron emission tomography, CT perfusion or MR perfusion before and after vasodilator stimulation. A second, indirect approach utilizes transcranial Doppler to assess flow velocities distal to the lesion, typically in the middle cerebral artery before and after vasodilatory stimulation, with increase in flow velocities used to indirectly measure CVR. 
Treatment
Treatment options for ECAS consist of medical therapy and in some cases, revascularization.
Medical therapy for carotid artery disease: Medical therapy is the cornerstone of treatment for atherosclerotic disease. Medical therapy for ECAS comprises of treatment of risk factors such as hypertension, dyslipidemia, diabetes mellitus, and tobacco use and use of antiplatelet therapy. Consensus societal class I recommendations for treatment of atherosclerotic carotid artery disease appear in Table 1 2002), and it appears that clopidogrel is superior to aspirin in preventing death, MI or stroke among those with a history of PAD (CAPRIE PAD subgroup analysis/paper). The benefit of dual antiplatelet therapy over monotherapy in this sub-group of patients is not as well-defined and was not proven in the MATCH or in the overall CHA-RISMA trial. Patients undergoing CABG who have atherosclerotic ECAS will benefit from antiplatelet monotherapy with at aspirin at a minimum; whether dual antiplatelet therapy is incrementally beneficial is less well established.
In summary, it is recommended that all patients with ECAS, regardless of whether they are to undergo CABG receive aggressive risk factor modification in addition to statins, beta-blockers, angiotensin converting enzyme inhibitors or angiotensin receptor blockers and antiplatelet therapy unless contraindicated.
Revascularization: The overall goal of carotid artery revascularization is to reduce the incidence of stroke beyond that afforded by medical therapy alone. In the perioperative setting, the decision about whether to perform carotid artery revascularization, which revascularization modality to pursue and when to revascularize (e.g., CEA or CAS preceded by CABG, CABG preceded by CEA or CAS, concomitant CEA or CAS at the time of CABG). remain challenging.
Indications for carotid revascularization: The decision to revascularize the carotid artery hinges on the presence or absence of symptoms attributable to ECAS, degree of ECAS and urgency of CABG.
The current multisocietal vascular guidelines recommend that carotid revascularization by CEA or CAS with embolic protection before or concurrent with myocardial revascularization surgery is reasonable in patients with greater than 80% carotid stenosis who have experienced ipsilateral retinal or hemispheric cerebral ischemic symptoms within 6 months. They also state that in patients with asymptomatic carotid stenosis, even if severe, the safety and efficacy of carotid revascularization before or concurrent with myocardial revascularization are not well established.. The American College of Cardiology and American Heart Association CABG guidelines state that is reasonable to revascularize ECAS of 50-99% in patients with previous history of stroke or TIA and In those who do not have a prior history of stroke or TIA, they consider it reasonable to revascularize especially in the setting of bilateral ECAS of 70-99% or unilateral ECAS of 70-99% with contralateral occlusion. (Hillis, Smith et al. 2011) In addition to it is necessary to identify and appropriately treat other factors such as atrial fibrillation, low output cardiac state, aortic arch atheroma, age, diabetes etc which also increase the risk for perioperative stroke.
Strategies for carotid revascularization in patients undergoing CABG:
The 2 revascularization modalities most commonly used are CEA and carotid stenting. Both of these modalities are approved by the Food and Drug Administration (FDA) for carotid revascularization. (FDA 2011)
Carotid endarterectomy: CEA has proven to beneficial in stroke reduction in patients with symptomatic and asymptomatic ECAS. (1991; 1991; 1995; 1996; 1998 There are three surgical strategies for carotid revascularization in patients undergoing CABG:
Concomitant CEA-CABG: CEA is performed prior CABG under the same anesthesia.
"Staged CEA-CABG": CEA is performed prior to CABG in different settings. Patient is initially schedule for CEA and then later for CABG, "Reverse staged": Here CABG is initially performed and then CEA is scheduled at a later date or time.
A meta-analysis of 56 reports comparing these 3 surgical strategies showed higher rates of stroke in patients undergoing reverse staged procedures (10%) as compared to concomitant (6%) and staged procedures (5%) However, staged procedures had the highest rates of perioperative MI ( 2) and death ± stroke rate was also higher compared to other staged procedure (8.7%, 95% CI 7.7-9.8). Reverse staged procedures had the highest risk of ipsilateral stroke (5.8%, 95% CI 0.0-14.3) and any stroke (6.3%, 95% CI 1.0-11.7) but with the lowest risk for peri-operative MI (0.9%, 95% CI 0.5-1.4). Staged procedures had the lowest rate of death ± stroke (6.1%, 95% CI 2.9-9.3) but the highest rate of peri-operative MI (6.5%, 95% CI 3.2-9.7). However, the benefit seen with staged procedures on reduction in stroke and death was no longer significant when peri-operative MI was also included in the combined outcomes. The risk of death/stroke/ MI was 11.5% (95% CI 10.1-12.9) following concomitant procedures versus 10.2% (95% CI 7.4-13.1) after staged procedures. Non of these studies had randomized patients to the different strategies and hence may have selection bias. Three different strategies can be utilized when carotid stenting is performed in patients undergoing CABG:
1. "Staged": CAS followed by CABG (CABG is done weeks later after CAS)
2. "Same day hybrid": CAS followed by CABG on the same day.
3. Concomitant ("true hybrid"): CAS followed by CABG on the same day in the same OR done immediately after CAS is completed.
In the staged method after carotid stenting, patients are treated with dual antiplatelet therapy with aspirin and clopidogrel for a few weeks (most commonly 4 weeks). Later, clopidogrel is held for 5-7 days prior to CABG. Patients undergoing hybrid procedures (true or same day) are placed on heparin between procedures and later on clopidogrel as soon as possible after CABG. Symptomatic carotid artery disease with ECAS >50-99% stenosis:
1. Symptomatic carotid disease and asymptomatic coronary disease or stable angina: In these patients carotid revascularization should be pursued prior to CABG, staged carotid stenting then followed by 4 weeks of dual antiplatelet and then CABG or staged CEA -CABG or concomitant CEA-CABD is usually considered. Selection of patients for carotid stenting or CEA is based co-morbidities, anatomy and local expertise available.
2.
Symptomatic carotid disease and symptomatic coronary disease (acute coronary syndromes): In these patients carotid disease should be revascularized initially or concomitantly. Concomitant CEA-CABG or "same day" or "true hybrid" stenting procedures are usually considered. In case need for emergent CABG's, reverse stages CABG-CEA procedures can be considered.
Asymptomatic carotid stenosis (ECAS> 80-99%) is further classified as high risk or low risk groups. High risk group consists of patients with bilateral ECAS > 80-99% or unilateral ECAS >80-99% with contralateral occlusion and asymptomatic ECAS 80-99% with impaired cerebral perfusion reserve. Patients without these features are considered low risk.
1.
Asymptomatic ECAS with high risk features and symptomatic coronary disease (acute coronary syndromes): These patients are at high risk for myocardial infarction as well as stroke and hence should be considered for concomitant CEA-CABG or "same day" or "true hybrid" CAS-CABG.
2.
Asymptomatic ECAS with high risk features with stable angina: These patients should be considered for staged CAS-CABG.
3. Asymptomatic ECAS with low risk features and stable angina or acute coronary syndromes: These patents should initially undergo coronary revascularization with carotid revascularization (stenting or CEA) at a later date on an elective basis. 
Conclusion
